Private Wealth Partners LLC has decreased its investment in Pfizer Inc. (NYSE: PFE) by 13.1% during the second quarter of the fiscal year. Following the sale of 77,813 shares, the firm now possesses 515,346 shares of the biopharmaceutical company, valued at approximately $12,492,000 as per the latest SEC filing. Pfizer now constitutes 1.0% of Private Wealth Partners’ overall portfolio, ranking as its 26th largest position.
Numerous institutional investors have also recently adjusted their positions in Pfizer. In the first quarter, GKV Capital Management Co. Inc. acquired a new stake valued at $27,000, while Curio Wealth LLC significantly increased its stake by 36,600% in the second quarter, bringing its total to 1,101 shares valued at $27,000 after adding 1,098 shares. Other firms, including North Capital Inc. and Bayforest Capital Ltd., also established new stakes, each valued at around $28,000.
Market Analyst Opinions on Pfizer
Analysts on Wall Street have expressed mixed views regarding Pfizer’s stock. Recently, Citigroup raised its price target for Pfizer from $25.00 to $26.00, maintaining a “neutral” rating. Conversely, Wall Street Zen downgraded the stock from a “buy” to a “hold” rating. Other firms, including Bank of America, have adjusted their target prices, with Bank of America predicting a rise from $28.00 to $30.00 and maintaining a “neutral” rating.
Investment sentiment is reflected in the ratings from multiple analysts: two have given a “Strong Buy,” four have recommended a “Buy,” eleven have issued a “Hold,” and one has rated it as a “Sell.” According to MarketBeat, Pfizer currently holds a consensus rating of “Hold” with a price target of $28.13.
Pfizer’s Recent Financial Performance and Dividend Announcement
On August 5, 2025, Pfizer reported its quarterly earnings, revealing $0.78 earnings per share, surpassing analysts’ expectations of $0.58 by $0.20. The company’s net margin stood at 16.84%, with a return on equity of 21.42%. Revenue for the quarter reached $14.65 billion, exceeding the anticipated $13.43 billion and reflecting a 10.3% increase from the same quarter in the previous year.
In addition to its earnings report, Pfizer announced a quarterly dividend of $0.43 per share, set to be distributed on December 1, 2025. Shareholders of record as of November 7, 2025 will receive this dividend. The company’s annualized dividend now amounts to $1.72, yielding approximately 6.9%. Pfizer’s payout ratio is reported at 91.49%.
Pfizer Inc. continues to play a significant role in the biopharmaceutical sector, focusing on the discovery, development, and manufacture of a wide range of medicines and vaccines, including treatments for cardiovascular diseases, infectious diseases, and COVID-19. As the company navigates the evolving market landscape, its financial health and strategic decisions will be closely monitored by investors and analysts alike.
